| 6.11 -0.26 (-4.08%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.21 |
1-year : | 8.87 |
| Resists | First : | 7.03 |
Second : | 7.59 |
| Pivot price | 6.71 |
|||
| Supports | First : | 6.11 |
Second : | 5.08 |
| MAs | MA(5) : | 6.54 |
MA(20) : | 6.8 |
| MA(100) : | 7.13 |
MA(250) : | 11.29 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.7 |
D(3) : | 15.8 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 18.12 | Low : | 5.69 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMA ] has closed below the lower bollinger band by 4.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ IMA ] is to continue within current trading range. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.24 - 6.28 | 6.28 - 6.3 |
| Low: | 6.02 - 6.07 | 6.07 - 6.11 |
| Close: | 6.05 - 6.12 | 6.12 - 6.17 |
C
Mon, 02 Mar 2026
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Thu, 26 Feb 2026
ImageneBio management plans fireside chat at Leerink healthcare conference - Stock Titan
Tue, 17 Feb 2026
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
Sat, 15 Nov 2025
Here's Why We're Watching ImageneBio's (NASDAQ:IMA) Cash Burn Situation - Yahoo Finance
Thu, 06 Nov 2025
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences - GlobeNewswire
Tue, 05 Aug 2025
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.26e+006 (%) |
| Held by Institutions | 15 (%) |
| Shares Short | 398 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.606e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 761.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 800000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -4.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 386450 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|